Steady Growth Forecast for Global Biopsy Guns Market

Small but steady growth lies ahead for the global biopsy guns market.

GlobalData estimates the sector has swelled 3% annually between 2015 and 2021 and projects it to continue growing at a similar rate through 2030. Events such as Movember, which is intended to raise awareness of men’s health, will fuel the sector’s steady expansion, the company claims. 
 
More than 700,000 people will die from prostate cancer globally by 2040, which is nearly double the 400,000 deaths in 2022, according to the International Agency for Research on Cancer. Early detection of this type of cancer using biopsy devices is therefore critical to improving recovery rates. While other cancerous indications like liver and lung cancers contribute to the market’s growth, prostate cancer is still an important indication for these needle biopsy devices.
 
“While not as prevalent as lung cancer or colorectal cancer, the projected increase in annual mortality for prostate cancer highlights the importance of detecting this cancerous type at the early stages in order to arrange suitable treatment,” said Brian Hicks, a senior analyst at GlobalData. “Two main risk factors for prostate cancer are aging and family history of the disease, so there is usually little that be done to prevent their development beyond leading a generally healthy lifestyle. However, in many cases, they can be diagnosed quickly to enable early intervention.”
 
Prostate screening tests are often performed for men older than 40 via digital rectal exams or prostate-specific antigen (PSA) tests. If prostate cancer is suspected due to an enlarged or hardened prostate, or to higher PSA levels, a biopsy is performed to properly diagnose and stage the cancer.
 
“A common approach to perform prostate biopsies is through mechanically assisted, ultrasound-guided thin needle biopsy of the prostate gland, where biopsy guns with needles less than 20 gauges are used to sample tissues. These devices have been instrumental in better diagnosing more prostate cancer cases, leading to their increased use globally over time,” Hicks said.